Work

“Matching” the “Mismatch” Repair–Deficient Prostate Cancer with Immunotherapy

Year: 2020

Type: article

Abstract: Mismatch repair gene mutations are uncommon in advanced prostate cancer; however, in those harboring these alterations, immune checkpoint blockade can be effective. As such, assays that can accurately identify these men are critically important. Cell-free circulating tumor DNA–based sequencing approaches appear to be one viable approach for identifying these patients. See related article by Ritch et al., p. 1114

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-19-3780

Authors: Michael T. Schweizer, Evan Y. Yu

Institutions: University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Prostate Cancer Foundation, National Cancer Institute